Latest News & Updates from the HEALEY ALS Platform Trial
Jul 15, 2024 · The ALS Association announced a $3 million commitment to the first platform trial for ALS, taking place at the Sean M. Healey & AMG Center for ALS at Mass General in collaboration with the Barrow Neurological Institute and the Northeast ALS Consortium (NEALS).
Sean M. Healey & AMG Center Announces Topline Results in HEALEY ALS …
For updates on the trial, please join our HEALEY ALS Platform Trial webinars. The HEALEY ALS Platform Trial is a patient-centric clinical trial designed in collaboration with the Northeast ALS Consortium (NEALS) to accelerate the development of breakthrough treatments for persons with ALS by testing multiple drugs (regimens) at the same time ...
Sean M. Healey & AMG Center Announces Update in ALS Platform Trial …
BOSTON – The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital today announced topline results from Regimen F of the HEALEY ALS Platform Trial evaluating f osigotifator (ABBV-CLS-7262) in people living with amyotrophic lateral sclerosis (ALS). Fosigotifator, an eIF2B activator, is an investigational drug being developed by Calico Life Sciences LLC (Calico) in ...
DNL343, fosigotifator fail HEALEY platform trial’s main goal in ALS
1 day ago · Testing DNL343, fosigotifator in HEALEY trial. The main goal of all the arms is to evaluate a treatment’s ability to slow ALS progression and prolong survival, as assessed by the ALS Functional Rating Scale-Revised (ALSFRS-R), after six months. New arms will be assessed for 36 weeks, or about nine months, following a recent amendment.
HEALEY ALS Trial Serves Up More Disappointment as Denali
1 day ago · Launched in 2020 to expedite the development of an effective medicine for amyotrophic lateral sclerosis, the HEALEY ALS Platform Trial suffered two more disappointments this week as candidates from Denali Therapeutics and AbbVie and Calico Life Sciences missed the study’s primary endpoint, failing to significantly slow disease progression.. Funded by Sean M. Healey—who died from ...
Fosigotifator Fails to Meet End Points in HEALEY-ALS Platform Trial
4 days ago · Topline data from regimen F of the HEALEY-ALS Platform trial revealed that fosigotifator (Calico Life Sciences), an investigational eIF2B activator, did not meet its primary end point of slowing disease progression in patients with amyotrophic lateral sclerosis (ALS). ... Sean M. Healey & AMG Center Announces Update in ALS Platform Trial with ...
Denali Therapeutics Announces Topline Results for Regimen G …
4 days ago · The HEALEY ALS Platform Trial is a large-scale collaborative effort made possible by contributions from patients and families, clinical trial sites, industry partners and research collaborators to evaluate multiple investigational therapies simultaneously with the goal of accelerating the development of potential new treatments for ALS.
HEALEY ALS trial to allow longer follow-up, blood cell collection
Dec 20, 2024 · The HEALEY ALS platform trial, which is simultaneously testing multiple potential treatments for amyotrophic lateral sclerosis (ALS), is amending its master protocol to allow a longer follow-up time and collection of blood cells for use in future research.
Denali Therapeutics Announces Topline Results for Regimen G …
4 days ago · Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial Denali Therapeutics Inc. Mon, Jan 6, 2025, 4:30 PM 7 min read
New Results From HEALEY ALS Platform Trial Show Promise for …
Oct 17, 2023 · Recently, based on results of the HEALEY ALS Platform Trial, two experimental medications plan to move to phase 3 clinical trials. This means the drugs will now be tested on a larger...
- Some results have been removed